International Cardiometabolic Expert To Join Racura Oncology’s Scientific Advisory Board

  • Racura Oncology appoints Associate Professor Erin Howden to scientific advisory board
  • Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients
  • Appointment aims to bring Racura Oncology’s new formulation of bisantrene to patients sooner

Special Report: Racura oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients.

Clinical-stage biopharmaceutical company Racura Oncology (ASX:RAC) has appointed Associate Professor Erin Howden, of the Baker Heart and Diabetes Institute in Melbourne, to its scientific advisory board. Read more here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.